Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 1, 2010, Pages 80-85

  Nofech Mozes, Sharon ^a   Khalifa, Mahmoud M ^a   Ismiil, Nadia ^a   Dubé, Valerie ^a   Saad, Reda S ^a   Sun, Peizhu ^a   Seth, Arun ^a   Ghorab, Zeina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

AMPLICOR; Cervical cancer; Clear cell carcinoma; HPV testing; Serous carcinoma; Small cell carcinoma

Indexed keywords

DNA; FORMALDEHYDE; PARAFFIN;

ADENOCARCINOMA; ADOLESCENT; ADULT; ARTICLE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SMALL CELL CARCINOMA; UTERINE CERVIX CARCINOMA; WART VIRUS;

DNA, VIRAL; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; PAPILLOMAVIRIDAE; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; UTERINE CERVICAL NEOPLASMS;

EID: 76149135057     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181ae7240     Document Type: Article

References (38)

1. Castellsague X, Diaz M, de SS, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-315.
2. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002;41:185-207.
3. Munoz N, Bosch FX, de SS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
4. Andersson S, Rylander E, Larsson B, et al. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer. 2001;37:246-250.
5. Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer. 2006;94:171-175.
6. Chew GK, Cruickshank ME, Rooney PH, et al. Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer. 2005;93:1301-1304.
7. Iwasawa A, Nieminen P, Lehtinen M, et al. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer. 1996;77: 2275-2279.
8. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
9. Nofech-Mozes S, Khalifa MA. Endocervical adenocarcinoma in situ, serous type. Int J Gynecol Pathol. 2009:140-141. [Epub ahead of print]
10. Nofech-Mozes S, Rasty G, Ismiil N, et al. Immunohistochemical characterization of endocervical papillary serous carcinoma. Int J Gynecol Cancer. 2006;16(suppl 1):286-292.
11. Goto K, Takeuchi Y, Yakihara A, et al. Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status. Gynecol Oncol. 2005;97:976-979.
12. Hadzisejdc I, Krasevic M, Haller H, et al. Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll Antropol. 2007;31(suppl 2):97-102.
13. Milde-Langosch K, Schreiber C, Becker G, et al. Human papillomavirus detection in cervical adenocarcinoma by polymerase chain reaction. Hum Pathol. 1993;24:590-594.
14. Riethdorf S, Riethdorf L, Milde-Langosch K, et al. Differences in HPV 16- and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri. Virchows Arch. 2000;437:491-500.
15. Stewart J, III, Bevans-Wilkins K, Ye C, et al. Clear-cell endocervical adenocarcinoma in a 19-year-old woman. Diagn Cytopathol. 2006; 34:839-842.
16. Tan YT, Zhang X, Lin ZQ, et al. Primary clear cell carcinoma of the cervix: report of five cases and review of the literature. Zhonghua Fu Chan Ke Za Zhi. 2008;43:120-123.
17. Hording U, Daugaard S, Visfeldt J. Adenocarcinoma of the cervix and adenocarcinoma of the endometrium: distinction with PCRmediated detection of HPV DNA. APMIS. 1997;105:313-316.
18. Alphandery C, Dagrada G, Frattini M, et al. Neuroendocrine small cell carcinoma of the cervix associated with endocervical adenocarcinoma: a case report. Acta Cytol. 2007;51:589-593.
19. Ambros RA, Park JS, Shah KV, et al. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol. 1991;4:586-593.
20. Herrington CS, Graham D, Southern SA, et al. Loss of retinoblastoma protein expression is frequent in small cell neuroendocrine carcinoma of the cervix and is unrelated to HPV type. Hum Pathol. 1999;30:906-910.
21. Ishida GM, Kato N, Hayasaka T, et al. Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. Int J Gynecol Pathol. 2004; 23:366-372.
22. Masumoto N, Fujii T, Ishikawa M, et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol. 2003;34:778-783.
23. Amplicor HPV, new diagnostic test to detect cancer causing viruses, launched in Europe. Roche web site [Accessed on: April 19, 2004 and May 30, 2008].
24. Molijn A, Kleter B, Quint W, et al. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol. 2005;32 (suppl 1): S43-S51.
25. Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol. 2006;44:2141-2146.
26. van Ham MA, Bakkers JM, Harbers GK, et al. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol. 2005;43: 2662-2667.
27. Halfon P, Trepo E, Antoniotti G, et al. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance. J Clin Microbiol. 2007;45: 313-316.
28. Rasty G, Bandarchi B, Siadat F, et al. Comparison of analytical sensitivity and specificity for hpv detection by chemiluminescent nucleic acid testing and pcr-based methods [abstract]. Mod Pathol. 2008;21(suppl 1):83A.
29. Rasty G, Bandarchi B, Siadat F, et al. Statistical analysis and diagnostic value of hpv detection by pcr-based method in formalin fixed, paraffin-embedded tissue [abstract]. Mod Pathol. 2008; 21(suppl 1):220A.
30. Minaguchi T, Yoshikawa H, Nakagawa S, et al. Association of PTEN mutation with HPV-negative adenocarcinoma of the uterine cervix. Cancer Lett. 2004;210:57-62.
31. Nucci MR, Lee KR, Crum C. Tumors of the female genital tract. In: Fletcher CDM. ed. Diagnostic Histopathology of Tumors. Boston: Churchill Livingstone Elsevier; 2007:697-718.
32. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
33. Liegl B, Regauer S. Penile clear cell carcinoma: a report of 5 cases of a distinct entity. Am J Surg Pathol. 2004;28:1513-1517.
34. Carlson JW, Nucci MR, Brodsky J, et al. Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis. Histopathology. 2007;51:305-312.
35. Stoler MH, Mills SE, Gersell DJ, et al. Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol. 1991;15:28-32.
36. Drubin DA, Laughlin-Drubin ME, Clawson GA, et al. A protease inhibitor specifically inhibits growth of HPV-infected keratinocytes. Mol Ther. 2006;13:1142-1148.
37. Huh WK, Roden RB. The future of vaccines for cervical cancer. Gynecol Oncol. 2008;109(2 suppl):S48-S56.
38. Lim MJ, Min SH, Lee JJ, et al. Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors. Mol Ther. 2006;13:899-909.